Who are aPCC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): aPCC, aPCC + TXA, Factor Concentrate (Bebulin), Haemocomplettan® P, Beriplex® P/N (Kcentra).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/apcc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

aPCC — Competitive Intelligence Brief

aPCC (aPCC) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prothrombin complex concentrate. Area: Hematology.

phase 3 Prothrombin complex concentrate Hematology Small molecule Live · refreshed every 30 min

Target snapshot

aPCC (aPCC) — Hoffmann-La Roche. aPCC is an anticoagulant that works by replacing and controlling the activity of natural anticoagulant proteins in the blood.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
aPCC TARGET	aPCC	Hoffmann-La Roche	phase 3	Prothrombin complex concentrate
aPCC, aPCC + TXA	aPCC, aPCC + TXA	Oslo University Hospital	marketed	Prothrombin complex concentrate with antifibrinolytic agent	Vitamin K-dependent clotting factors (II, VII, IX, X); plasminogen
Factor Concentrate (Bebulin)	Factor Concentrate (Bebulin)	The University of Texas Health Science Center, Houston	marketed	Prothrombin complex concentrate (PCC)	Coagulation factors II, VII, IX, X
Haemocomplettan® P	Haemocomplettan® P	CSL Behring	marketed	Prothrombin complex concentrate (PCC)	Clotting factors II, VII, IX, X
Beriplex® P/N (Kcentra)	Beriplex® P/N (Kcentra)	CSL Behring	phase 3	Prothrombin complex concentrate (PCC)	Vitamin K-dependent clotting factors (Factors II, VII, IX, X)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prothrombin complex concentrate class)

Hoffmann-La Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). aPCC — Competitive Intelligence Brief. https://druglandscape.com/ci/apcc. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab